HIV reverse transcriptase and HIV protease — Drug Target

All drugs that target HIV reverse transcriptase and HIV protease — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) · Antiretroviral combination therapy (NRTI + PI) · Antiretroviral combination therapy (NRTI + protease inhibitor)

Marketed (3)

• TAF with a boosted protease inhibitor · University of Colorado, Denver · Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor) · Infectious Disease / Virology
  TAF (tenofovir alafenamide) is a nucleotide reverse transcriptase inhibitor that, when combined with a boosted protease inhibitor, blocks HIV replication by inhibiting both reverse transcriptase and protease enzymes.
• zidovudine+lamivudine+lopinavir/ritonavir · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Antiretroviral combination therapy (NRTI + PI) · Infectious Disease / Virology
  This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.
• Combivir+Kaletra · Hospital Clinic of Barcelona · Antiretroviral combination therapy (NRTI + protease inhibitor) · Infectious Disease / Virology
  This combination of two antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication.